Your browser doesn't support javascript.
loading
Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium.
Møller, Pål; Seppälä, Toni; Dowty, James G; Haupt, Saskia; Dominguez-Valentin, Mev; Sunde, Lone; Bernstein, Inge; Engel, Christoph; Aretz, Stefan; Nielsen, Maartje; Capella, Gabriel; Evans, Dafydd Gareth; Burn, John; Holinski-Feder, Elke; Bertario, Lucio; Bonanni, Bernardo; Lindblom, Annika; Levi, Zohar; Macrae, Finlay; Winship, Ingrid; Plazzer, John-Paul; Sijmons, Rolf; Laghi, Luigi; Valle, Adriana Della; Heinimann, Karl; Half, Elizabeth; Lopez-Koestner, Francisco; Alvarez-Valenzuela, Karin; Scott, Rodney J; Katz, Lior; Laish, Ido; Vainer, Elez; Vaccaro, Carlos Alberto; Carraro, Dirce Maria; Gluck, Nathan; Abu-Freha, Naim; Stakelum, Aine; Kennelly, Rory; Winter, Des; Rossi, Benedito Mauro; Greenblatt, Marc; Bohorquez, Mabel; Sheth, Harsh; Tibiletti, Maria Grazia; Lino-Silva, Leonardo S; Horisberger, Karoline; Portenkirchner, Carmen; Nascimento, Ivana; Rossi, Norma Teresa; da Silva, Leandro Apolinário.
Afiliação
  • Møller P; Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, 0379, Oslo, Norway. moller.pal@gmail.com.
  • Seppälä T; Department of Gastrointestinal Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
  • Dowty JG; Applied Tumour Genomics Research Program, University of Helsinki, Helsinki, Finland.
  • Haupt S; Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
  • Dominguez-Valentin M; Centre of Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, 3010, Australia.
  • Sunde L; Engineering Mathematics and Computing Lab (EMCL), Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg, Germany.
  • Bernstein I; Data Mining and Uncertainty Quantification (DMQ), Heidelberg Institute for Theoretical Studies (HITS), Heidelberg, Germany.
  • Engel C; Department of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, 0379, Oslo, Norway.
  • Aretz S; Department of Clinical Genetics, Aalborg University Hospital, 9000, Aalborg, Denmark.
  • Nielsen M; Department of Biomedicine, Aarhus University, DK-8000, Aarhus, Denmark.
  • Capella G; Department of Surgical Gastroenterology, Aalborg University Hospital, Aalborg University, 9100, Aalborg, Denmark.
  • Evans DG; Institute of Clinical Medicine, Aalborg University Hospital, Aalborg University, 9100, Aalborg, Denmark.
  • Burn J; Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, 04107, Leipzig, Germany.
  • Holinski-Feder E; Institute of Human Genetics, National Center for Hereditary Tumor Syndromes, Medical Faculty, University of Bonn, 53127, Bonn, Germany.
  • Bertario L; Department of Clinical Genetics, Leids Universitair Medisch Centrum, 2300RC, Leiden, The Netherlands.
  • Bonanni B; Hereditary Cancer Program, Institut Català d'Oncologia-IDIBELL, L; Hospitalet de Llobregat, 08908, Barcelona, Spain.
  • Lindblom A; Division of Evolution and Genomic Sciences, Manchester Centre for Genomic Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, M13 9WL, UK.
  • Levi Z; Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE1 3BZ, UK.
  • Macrae F; Campus Innenstadt, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, 80336, Munich, Germany.
  • Winship I; MGZ - Center of Medical Genetics, 80335, Munich, Germany.
  • Plazzer JP; Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141, Milan, Italy.
  • Sijmons R; Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, 20141, Milan, Italy.
  • Laghi L; Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76, Stockholm, Sweden.
  • Valle AD; Department Rabin Medical Center, Service High Risk GI Cancer Gastroenterology, Petach Tikva, Israel.
  • Heinimann K; Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, Australia.
  • Half E; Department of Medicine, Melbourne University, Melbourne, Australia.
  • Lopez-Koestner F; Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Melbourne, Australia.
  • Alvarez-Valenzuela K; Department of Medicine, Melbourne University, Melbourne, Australia.
  • Scott RJ; The Royal Melbourne Hospital, Melbourne, Australia.
  • Katz L; Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Laish I; Department of Medicine and Surgery, Laboratory of Molecular Gastroenterology, IRCCS Humanitas Research Hospital, University of Parma, Parma, Italy.
  • Vainer E; Hospital Fuerzas Armadas, Grupo Colaborativo Uruguayo, Investigación de Afecciones Oncológicas Hereditarias (GCU), Montevideo, Uruguay.
  • Vaccaro CA; Medical Genetics, Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Carraro DM; Gastrointestinal Cancer Prevention Unit, Gastroenterology Department, Rambam Health Care Campus, Haifa, Israel.
  • Gluck N; Programa Cáncer Heredo Familiar Clínica Universidad de los Ande, Santiago, Chile.
  • Abu-Freha N; Programa Cáncer Heredo Familiar Clínica Universidad de los Ande, Santiago, Chile.
  • Stakelum A; University of Newcastle and the Hunter Medical Research Institute, Callaghan, Australia.
  • Kennelly R; Department of Gastroenterology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Winter D; The Department of Gastroenterology, High Risk and GI Cancer Prevention Clinic, Gastro-Oncology Unit, Sheba Medical Center, Ramat Gan, Israel.
  • Rossi BM; Department of Gastroenterology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Greenblatt M; Hereditary Cancer Program (PROCANHE), Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
  • Bohorquez M; Genomic and Molecular Biology Group, A.C.Camargo Cancer Center, Sao Paulo, Brazil.
  • Sheth H; Department of Gastroenterology, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Tibiletti MG; The Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer Sheva, Israel.
  • Lino-Silva LS; St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
  • Horisberger K; St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
  • Portenkirchner C; St Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
  • Nascimento I; Hospital Sirio Libanes, Sao Paulo, Brazil.
  • Rossi NT; University of Vermont, Larner College of Medicine, Burlington, VT, 05405, USA.
  • da Silva LA; University of Tolima, Tolima, Colombia.
Hered Cancer Clin Pract ; 20(1): 36, 2022 Oct 01.
Article em En | MEDLINE | ID: mdl-36182917
ABSTRACT

OBJECTIVE:

To compare colorectal cancer (CRC) incidences in carriers of pathogenic variants of the MMR genes in the PLSD and IMRC cohorts, of which only the former included mandatory colonoscopy surveillance for all participants.

METHODS:

CRC incidences were calculated in an intervention group comprising a cohort of confirmed carriers of pathogenic or likely pathogenic variants in mismatch repair genes (path_MMR) followed prospectively by the Prospective Lynch Syndrome Database (PLSD). All had colonoscopy surveillance, with polypectomy when polyps were identified. Comparison was made with a retrospective cohort reported by the International Mismatch Repair Consortium (IMRC). This comprised confirmed and inferred path_MMR carriers who were first- or second-degree relatives of Lynch syndrome probands.

RESULTS:

In the PLSD, 8,153 subjects had follow-up colonoscopy surveillance for a total of 67,604 years and 578 carriers had CRC diagnosed. Average cumulative incidences of CRC in path_MLH1 carriers at 70 years of age were 52% in males and 41% in females; for path_MSH2 50% and 39%; for path_MSH6 13% and 17% and for path_PMS2 11% and 8%. In contrast, in the IMRC cohort, corresponding cumulative incidences were 40% and 27%; 34% and 23%; 16% and 8% and 7% and 6%. Comparing just the European carriers in the two series gave similar findings. Numbers in the PLSD series did not allow comparisons of carriers from other continents separately. Cumulative incidences at 25 years were < 1% in all retrospective groups.

CONCLUSIONS:

Prospectively observed CRC incidences (PLSD) in path_MLH1 and path_MSH2 carriers undergoing colonoscopy surveillance and polypectomy were higher than in the retrospective (IMRC) series, and were not reduced in path_MSH6 carriers. These findings were the opposite to those expected. CRC point incidence before 50 years of age was reduced in path_PMS2 carriers subjected to colonoscopy, but not significantly so.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hered Cancer Clin Pract Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Noruega

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hered Cancer Clin Pract Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Noruega